Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis
Phytotherapy Research · 2026-11 · 40 (11) · 6791-6808
DOI: 10.1002/ptr.70460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 24.09.2026. Verfasst von Han-Chen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Chinese Medicinal Resource From Lingnan, Ministry of Education, School of Pharmaceutical Sciences, Guangzhou University of Chinese …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Plant Extracts, Asteraceae. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Guangdong Province Modern Agricultural Industrial Technology System Innovation Team Construction Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Activation of cGAS/STING/IFN‐I signaling pathway serves as a potential therapeutic strategy to enhance CD8 + T cells infiltration and augment antitumor immunotherapy. The medicinal herb Centipeda minima has been traditionally employed to treat respiratory diseases and cancer; however, whether C. minima and its bioactive constituents can activate CD8 + T cell‐mediated antitumor immunity in non‐small cell lung cancer (NSCLC) remains elusive. In this study, the ethanol extract of C. minima (ECM) significantly enhanced the cytotoxic activity of human peripheral blood mononuclear cell‐derived activated T cells and murine primary CD8 + T cells against NSCLC cells, and promoted CD8 + T cell infiltration in the LLC syngeneic tumor model. RNA‐seq profiling indicated that ECM potentially triggers type‐I interferon (IFN‐I)‐mediated innate immunity in NSCLC. Mechanistically, ECM treatment activated the cGAS/STING pathway in NSCLC cells, as evidenced by increased phosphorylation of TBK1 and IRF3, elevated IFN‐I gene expression, and enhanced CD8 + T cells activity. Notably, ECM markedly downregulated both mitochondrial and nuclear FANCD2 protein levels, which may facilitate cytosolic release of mitochondrial and nuclear DNA, thereby stimulating the cGAS/STING/IFN‐I signaling axis. ECM‐induced FANCD2 downregulation was markedly reversed by the proteasome inhibitor MG‐132. Combination treatment with ECM and anti‐PD‐1 antibody synergistically suppressed tumor growth in the LLC syngeneic model, accompanied by elevated IFN‐I expression and pronounced recruitment of activated CD8 + T cells. Moreover, 3‐ O ‐methylquercetin and several sesquiterpene lactones abundant in ECM were identified to downregulate FANCD2, activate TBK1/IRF3 pathway, and enhance IFN‐I expression in NSCLC cells. Among these active compounds, arnicolide D promoted FANCD2 degradation in a proteasome‐dependent manner, whereas 3‐ O ‐methylquercetin predominantly suppressed FANCD2 gene expression. Collectively, our findings suggest that FANCD2 may serve as a novel therapeutic target for enhancing antitumor innate immunity, and that C. minima along with its active compounds can potentiate antitumor immunotherapy by activating the FANCD2‐cGAS/STING/IFN‐I signaling axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Chinese Medicinal Resource From Lingnan, Ministry of Education, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Research Center of Chinese Herbal Resource Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences, G…
- Institute of Cancer Research, Henan Academy of Innovations in Medical Sciences, Zhengzhou, China.
- Key Laboratory of Chronic Disease Prevention and Control of Traditional Chinese Medicine of Guangdong Higher Education Institutes, Guangzhou University of Chinese Medicine, KLGHEI (2024KSYS024), Guangzhou, China.
ORCID-Profile: Han-Chen Wang, Chu-Ying Chen, Jiang-Tao Xiao, Tao Su, Guang-Biao Zhou, Yong-Qiang Liu
Förderung
- National Key Research and Development Program of China
- Guangdong Province Modern Agricultural Industrial Technology System Innovation Team Construction Project
- National Natural Science Foundation of China
- Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases
- First-Class Discipline Capacity Enhancement Program of Guangzhou University of Chinese Medicine
Zitieren
APA
Wang, H. C., Chen, C. Y., Xiao, J. T., Zheng, R. Q., He, W. D., Xu, Z. W., Wei, S. F., Su, T., Zhou, G. B., & Liu, Y. Q. (2026). Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis. Phytotherapy Research, 40(11), 6791-6808. https://doi.org/10.1002/ptr.70460
Vancouver
Wang HC, Chen CY, Xiao JT, Zheng RQ, He WD, Xu ZW, et al. Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis. Phytotherapy Research. 2026;40(11):6791-6808. doi:10.1002/ptr.70460
BibTeX
@article{Wang2026,
author = {Wang, Han-Chen and Chen, Chu-Ying and Xiao, Jiang-Tao and Zheng, Rou-Qiao and He, Wen-Da and Xu, Zi-Wei and Wei, Su-Fen and Su, Tao and Zhou, Guang-Biao and Liu, Yong-Qiang},
title = {Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {11},
pages = {6791--6808},
doi = {10.1002/ptr.70460}
}
EUVIMED